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ABSTRACT
Background: The TORCH phase III trial compared the efficacy of first-line 
erlotinib followed by chemotherapy at progression (experimental arm) with the 
reverse sequence (standard arm) in unselected advanced non-small cell lung cancer 
(NSCLC) patients. Here we report biomarker analyses.
Methods: EGFR and KRAS mutation, expression of EGFR family members and 
of cMET and PTEN and EGFR and ABCG2 germline polymorphisms were tested on 
tumor tissue or blood samples to either confirm previously proposed predictive role or 
describe it in an explorative setting. Progression-free survival (PFS) was the primary 
end-point, overall survival, response rate and side effects (diarrhoea and skin toxicity) 
were secondary end-points. Interactions between biomarkers and treatment were 
studied with multivariable models (either Cox model or logistic regression). Statistical 
analyses accounted for multiple comparisons. 
Results: At least one biomarker was assessed in 324 out of 760 patients in the 
TORCH study. EGFR mutation was more common in female (P = 0.0001), East Asians 
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INTRODUCTION
The discovery of oncogenic mutations in the 
tyrosine kinase (TK) domain of the epidermal growth 
factor receptor (EGFR) gene, and sensitivity of mutant 
lung cancers to EGFR-TK inhibitors (TKIs), have 
revolutionized the treatment of advanced NSCLC. 
Erlotinib, one of the first generation EGFR-TKIs, has 
become a standard first line drug for patients with EGFR 
mutant lung cancers.[1] However, only 60-80% of NSCLC 
patients with EGFR mutant tumour respond to EGFR-
TKI therapy,[2-5] while a small proportion of patients 
with EGFR wild-type tumors may also benefit from this 
class of drugs.[6, 7] Primary resistance to EGFR-TKIs 
has been attributed to various factors, including EGFR 
exon 20 insertion mutations.[8, 9] Patients whose tumors 
harbor KRAS mutation are rarely responsive to EGFR-
TKIs and KRAS mutation might serve as a predictor of 
resistance to EGFR-TKIs.[10, 11] Activation of alternative 
signaling pathways including mutations in BRAF, PIK3CA 
and loss of PTEN have also been implicated as resistance 
mechanisms in preclinical studies.[12, 13] In addition, 
germline polymorphisms involving the promoter and 
intron 1 transcription enhancer regions of the EGFR gene 
and the ABCG2 multidrug transporter gene have also been 
reported as modifiers of response to EGFR-TKI therapy. 
[14-16] 
The TORCH (Tarceva OR CHemotherapy) trial was 
an Italian-Canadian multicenter, open-label, randomized 
phase III trial comparing first line erlotinib followed by 
chemotherapy (cisplatin-gemcitabine) at progression, with 
the reverse standard sequence of first-line chemotherapy 
followed by erlotinib, in unselected advanced stage IIIB 
and IV, predominantly Caucasian, NSCLC patients.[17] 
The study was terminated early due to inferiority of the 
experimental arm (erlotinib first) in terms of overall 
survival (OS). In this manuscript, we summarize the 
results of confirmatory and exploratory analyses of 
the impact of biomarkers on clinical outcomes in this 
trial including EGFR gene copy number gains, KRAS 
mutations, immunohistochemical expression of EGFR 
family members, cMET and PTEN, and EGFR and 
ABCG2 germline polymorphisms, in addition to EGFR 
mutations that have already been partially reported.[17] 
RESULTS
Details of patients’ flow and samples available for 
each biomarker are reported in Supplementary Figure S2. 
556 patients consented to biomarker studies and at least 
one biomarker was tested for 324 (42.6%) patients (study 
population). Baseline characteristics of the biomarker 
population were comparable to both the population of 
patients (N = 673) enrolled in centers that provided at least 
one sample and the whole trial patient population (N = 
760) (Supplementary Table S2).
Distribution of biomarkers categories is reported in 
Table 1. All biomarkers were balanced between treatment 
arms. Due to low prevalence or absence of positive cases, 
HER2 and HER3 were excluded from further analyses.
Associations between each biomarker and baseline 
patients characteristics are described in Supplementary 
Tables S3 to S13. According to the predefined 0.001 
threshold for statistical significance, EGFR mutation 
was significantly more common in female (p = 0.0001), 
East Asians (P < 0.0001) and never smoker (P < 0.0001) 
patients; low MET protein expression by IHC (H-score < 
200) was more frequent in case of squamous carcinoma 
(P = 0.00009) and ABCG2 C/A or A/A polymorphism was 
more frequent among East-Asian patients (P = 0.0003). 
Pairwise association between biomarkers is 
reported in Supplementary Table S14. No association 
was significant at the predefined level of 0.001, with the 
exception of the obvious one between the two scoring 
systems for MET protein expression by IHC. 
The modifying effects of biomarkers on PFS, OS 
and response to first treatment are provided in Figures 1 
to 3. A significant interaction was only found for EGFR 
mutation in PFS (Figure 1) and response rate analyses 
(Figure 3) while no predictive effect on OS was found for 
any biomarker (Figure 2) at the predefined Bonferroni-
Holm sequential significance levels. 
In an exploratory unplanned analysis of patients 
with non-mutated EGFR or EGFR mutation unknown 
status, ABCG2 polymorphism had a significant (P = 
0.003) interaction with treatment effect on PFS (HR for 
erlotinib vs chemotherapy was 0.62, 95%CI 0.28-1.34 
among A/C or A/A and 2.07, 95%CI 1.54-2.80 among 
C/C ABCG2 polymorphisms). Further, adjustment for the 
Asian ethnicity, which was significantly more common in 
(P < 0.0001) and never smoker (P < 0.0001) patients; low MET protein expression by 
IHC (H-score <200) was more frequent in squamous (P < 0.00009) and ABCG2 C/A 
or A/A polymorphism was more frequent among East-Asian patients (P = 0.0003). A 
significant interaction was found for EGFR mutation in PFS and response rate analyses 
while no predictive effect on OS was found for any biomarker. No biomarker tested 
was prognostic for PFS and OS. No polymorphism was significantly associated with 
skin toxicity or diarrhea. 
Conclusion: In the present study, beyond the known role of EGFR mutation, no 
other biomarker has predictive or prognostic role.
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the A/C or A/A arm when compared to the C/C arm, led to 
similar results. 
None of the tested biomarkers was prognostic for 
PFS and OS at the pre-defined significance level of 0.01 
(Table 2). 
None of the polymorphisms evaluated were 
significantly associated with skin toxicity or diarrhea 
(Supplementary Table S15). 
DISCUSSION
As an ancillary analysis of the TORCH trial, 
we explored potential biomarkers for predicting the 
response or resistance to the EGFR-TKIs compared 
with chemotherapy. We assessed both biomarker-by-
treatment interactions and prognostic value of the 
proposed biomarkers. Follow-up data were mature 
and a conservative statistical analysis plan was applied 
accounting for multiplicity of comparisons and reducing 
the expected inflation of false positive results. As a major 
limitation, however, biomarkers’ evaluation was not 
mandatory in the trial and was actually performed only in 
43% of the patients; nonetheless, this rate compares well 
with other trials in advanced lung cancer where biologic 
sample collection was not mandatory.
Except for EGFR mutation,[17] we failed to confirm 
the predictive role of any other biomarker, including high 
expression of HER2, HER3, cMET and loss of PTEN 
expression, that were studied due to their potential role 
in activating bypass survival pathway downstream of 
EGFR.[18, 19] Among these markers, we found no or 
very few cases with high expression of HER2 and HER3. 
Interestingly, the first treatment progression free hazard 
ratio for high and low cMET expression (H-score ≥200 
vs < 200) was 3.04 vs. 1.45, with borderline interaction 
p value of 0.056. These results confirm that first line 
chemotherapy is superior to erlotinib irrespective of cMET 
expression level, however suggesting that any potential 
activity of erlotinib is significantly less in tumor that 
express very high level of cMET. Unfortunately, the low 
number of patients with EGFR mutant tumor exclude us 
from studying potential role of high MET expression as 
a potential negative predictive marker in first line EGFR 
TKI therapy.
The predictive role of EGFR gene copy number as 
determined by fluorescence in situ hybridization (FISH) 
Figure 1: Forest plot of progression free survival by treatment arm and biomarkers. Hazard ratio (HR) < 1 means a lower 
risk of progression or death for patients treated with first-line erlotinib. 
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Table 1: Distribution of biomarkers according to treatment arm, within the biomarker population (n=324 patients 
with at least one biomarker available)
*Chi square test, comparing Standard and Experimental Arms; EGFR CA repeat S (short): ≤16CA repeat; L (Long): ≥17CA 
repeat; Unknowns are due to lack of remaining material available for biomarker assessment. 
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is a matter of controversy.[3, 20-22] As high percentages 
of EGFR mutant NSCLC also demonstrate amplification 
of the gene, it was postulated that the predictiveness of 
EGFR high gene copy number could be accounted by the 
presence of mutation. In fact, in the IPASS patients, EGFR 
FISH was not predictive in EGFR wild type patients.[23] 
The results of our analysis in the TORCH patients confirm 
this finding (Supplementary Figure S3). 
Despite suggestions that germline polymorphisms 
may be associated with erlotinib efficacy, none has 
consistently been associated with survival or response.[15, 
16] In the TORCH trial, we found a significant interaction 
between the ABCG2 +421 polymorphism and PFS. The 
non significant finding of interaction for OS (P = 0.11) 
may have been favoured by the cross-over design. In this 
trial, the vast majority of patients likely carried wild type 
EGFR, which is the primary driver of best initial response. 
In contrast, wild type EGFR produces mostly stable 
disease responses, and thus it was unlikely that initial 
response would be differentiated in this population by 
genetic polymorphisms; indeed we found no relationship 
between any of the polymorphisms and best initial 
response to therapy. Two exploratory analyses of ABCG2 
+421 were performed. This ABCG2 polymorphism had 
been evaluated in one other randomized control trial 
involving erlotinib as the experimental drug but in a 
different setting: the BR.21 trial of chemo-refractory 
placebo-controlled metastatic/advanced stage patients 
found no significantly interaction associations between 
this polymorphism and the trial arm for any treatment 
outcomes.[15] The same polymorphisms may affect 
toxicity.[15, 24] However, in the TORCH trial, we found 
no significant or even trends in relationship with any of the 
main toxicities of erlotinib, but small samples sizes limited 
any firm conclusions.
In conclusion, an extensive exploratory biomarker 
analysis in TORCH trial failed to identify additional 
predictive or prognostic biomarkers beyond EGFR 
mutation in first line erlotinib therapy. 
MATERIALS AND METHODS
The details of the TORCH clinical trial eligibility 
and conduct have been described previously.[17]
Figure 2: Forest plot of overall survival by treatment arm and biomarkers. Hazard ratio (HR) < 1 means a lower risk of death 
for patients treated with first-line erlotinib. 
Oncotarget57533www.impactjournals.com/oncotarget
Formalin fixed paraffin embedded blocks or 
unstained sections of tumor tissue were collected. 
Because of limited tissue materials, biomarker analyses 
were performed in the following priority order: EGFR 
mutation status, KRAS mutation, EGFR gene copy number 
(GCN) by fluorescent in situ hybridization (FISH), EGFR, 
cMET, HER2, HER3 and PTEN protein expression by 
immunohistochemistry. The remaining material was used 
for genotyping of EGFR and ABCG2 polymorphisms 
(when no blood sample or tissue block of normal tissue 
was available). No prioritization was required for blood 
sample derived DNA. 
All biomarker assays were performed at the Applied 
Molecular Profiling Laboratory at the Princess Margaret 
Cancer Centre. All tissue analyses were preceded by a 
pathology review of the hematoxylin eosin (HE) stained 
slides to confirm the diagnosis, estimate the tumor cell 
abundance and mark the tumor areas for macrodissection 
or FISH scoring. The procedure of the EGFR mutation 
test and EGFR/ABCG2 polymorphism analysis has been 
described previously.[15, 17, 25]
EGFR exon 19 deletion and exon 21 L858R 
mutations were analysed as previously reported.[17] 
KRAS codon 12 and 13 mutations were analysed using 
the capilllary sequencing method, with positive or 
equivocal results confirmed by repeat sequencing. EGFR 
gene copy number was evaluated by fluorescence in situ 
hybridization; high and low copy number cases were 
categorized using the University of Colorado system, as 
reported previously.[25] 
IHC staining was performed using the BenchMark 
XT autostainer (Ventana, Tucson, AZ). The antibodies, 
staining conditions and scoring cut-offs used are detailed 
in Supplementary Table S1. For each marker, the staining 
intensity (grades 0 to 3) and estimated percentage (%) of 
tumor cells at each intensity grade were recorded. The 
H-score was the sum of % stained tumor cells at each 
staining intensity. For EGFR, HER2 and HER3, cases 
were classified as low or high expression, using H-score 
< 200 and ≥200, respectively. Two scoring systems were 
used for cMET: (1) MET-H200 scoring system using 
H-score < 200 and ≥200 as above; and (2) the MET 
Figure 3: Forest plot of response by treatment arm and biomarkers. Odds ratio (OR) >1 means a higher probability of response 
for patients treated with first-line erlotinib. 
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IHC scoring system that was developed in a previous 
trial.[26] The latter score was assessed independently 
by two pathologists (LK and MST) and the final MET-
IHC represents the mean of the two independent scores 
(Supplementary Figure S1). PTEN IHC was interpreted 
as negative when there was no staining at all.[27] All 
interpretation was performed without information on 
clinical outcome and assigned treatment strategy. 
Blood samples were collected using a kit provided 
by the central laboratory with specific processing and 
shipment instructions. DNA was isolated using the 
Qiagen humanDNA kit. Polymorphism analyses for EGFR 
promoter (-216 G>T, rs712829 and -191 C>A rs712830), 
EGFR intron 1CA repeat polymorphisms and for the 
ABCG2 +421 C>A (rs2231142) polymorphisms have 
been described previously.[15, 16] In brief, analyses were 
conducted using direct Sanger sequencing and Taqman 
polymerase chain reaction (PCR) reaction. For patients 
without blood samples, analyses were conducted using 
DNA isolated from FFPE tumor samples used for mutation 
analyses, as a surrogate material. Our prior work has 
shown this region to be highly preserved when comparing 
germline to somatic material from lung cancer, with >90% 
agreement in paired blood-tumor tissue analyses.[15, 16]
The statistical analysis plan is detailed in the 
Supplementary materials on line. Several biomarkers were 
evaluated in confirmatory (EGFR mutation, EGFR gene 
copy, EGFR IHC, KRAS mutation, polymorphic variants 
of EGFR (SNP 216, SNP 191, CA repeat) and ABCG2) 
and exploratory (PTEN, MET.H200, MET IHC, HER2, 
HER3) analyses. Because of multiplicity of comparisons 
different significance levels were used according to a pre-
defined step-down Holm-Bonferroni sequential testing 
procedure. 
All efficacy analyses were based on intention-to-
treat strategy. The primary end-point was progression-free 
Table 2: Prognostic role of biomarkers with no significant interaction with treatment 
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survival (PFS) to first treatment, while overall survival 
(OS) and response rate to first treatment (RR) were 
secondary end-points. 
Both predictive and prognostic roles of biomarkers 
were evaluated using the appropriate multivariable 
models. 
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